38 Versus Just 2: How US Expedites Novel Drug Reviews While EU Falls Behind

 
• By Neena Brizmohun
  
Between August 2024 and August 2025, around 63% of the novel drugs approved in the US received an expedited regulatory review, compared to around just 4% in the EU. (Shutterstock)

More from Review Pathways

More from United States